Clinical trials
Epithelioid Hemangioendothelioma clinical trials
Below are recruiting epithelioid hemangioendothelioma clinical trials, each written for real people, not researchers. We’re tracking 6 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07104331RecruitingPhase 2
Testing nab-sirolimus for epithelioid hemangioendothelioma
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
Stanford, CaliforniaAges 18 years+ - NCT06408441Recruiting
EHE registry for rare adult cancers
This study collects information from European hospitals on people with epithelioid hemangioendothelioma (EHE), a rare tumor that grows in blood vessels. Joining this registry helps doctors learn more about the disease and improve care for others.
Graz, GrazAges 18 years+ - NCT03967834Recruiting
Study of immune features in rare soft tissue sarcoma
This study looks at immune system “fingerprints” using tumor tissue from people with rare soft tissue sarcoma. It may help researchers understand what drives these cancers and guide future treatments.
BesançonAges 18 years+ - NCT06239272RecruitingPhase 1/Phase 2
Personalized treatment for NRSTS in children and young adults
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
Atlanta, GeorgiaAges Up to 30 years - NCT06452160RecruitingPhase 1
Study of BGC515 for advanced solid tumors
This trial tests an experimental drug called BGC515 for people with advanced solid tumors, including mesothelioma and EHE, that have not responded to standard treatments. The drug works by targeting a specific cell signaling pathway (Hippo) that may be involved in cancer growth.
Houston, TexasAges 18 years+ - NCT06541652Recruiting
Study of rare liver cancers in France
This study looks at people with rare types of liver cancer to learn more about the disease. If you have one of these rare liver cancers, your information could help doctors understand these cancers better.
AmiensAges 18 years+
Hear when a new Epithelioid Hemangioendothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for epithelioid hemangioendothelioma?
- Yes. Clin2 currently lists 6 recruiting epithelioid hemangioendothelioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a epithelioid hemangioendothelioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a epithelioid hemangioendothelioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.